Skip to Main Content

Alkermes (ALKS) said Thursday that schizophrenia patients treated with an experimental tablet called ALKS 3831 reported significantly less weight gain compared to the most commonly prescribed antipsychotic currently in use.

The ALKS 3831 results achieved the main goal of Alkermes’ Phase 3 clinical trial, clearing the way for the biopharma company to file for regulatory approval in the middle of next year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.